Detailed Narrative
Revita Midpoint Cohort 1-Year Data Reinforces Durability
Fractyl Health reported compelling one-year randomized data from the Remain One midpoint cohort for its Revita procedure. Patients maintained over 80% of their prior GLP-1 induced weight loss, significantly outperforming the 46% seen in the sham arm. This data, consistent with the Open Label Reveal One cohort (78% weight maintenance), directly addresses concerns about the durability of Revita's effect and suggests a plateau in weight regain at the one-year mark. The strongest results were observed in patients with complete ablations and higher run-in weight loss, variables for which the pivotal study is enriched.
Pivotal Study Designed for Success with Strong Safety Profile
The larger Remain One Pivotal cohort, with over 300 participants across 30+ sites, is designed to replicate and expand upon the midpoint cohort's success. It is enriched for complete ablation length (median 16cm vs. 14cm threshold) and higher run-in weight loss (mean 18.3% vs. 17.5% threshold). Both co-primary endpoints (percent total body weight regained at six months and responder rate at 12 months) are estimated to be powered above 95%. The procedure has demonstrated an unusually clean safety profile, with zero device or procedure-related serious adverse events in the midpoint cohort over one year, which is expected to drive physician and patient adoption.
Expanding Commercial Opportunity Driven by GLP-1 Market Dynamics
The company views the evolving GLP-1 market as a significant driver for Revita's commercial opportunity, expanding the addressable market and improving economics. With 30 million Americans on GLP-1 therapy and 1 million discontinuing monthly, Revita offers a durable, drug-free weight maintenance option. FDA Breakthrough Device designation and CMS's new GLP-1 Bridge demonstration highlight the recognized need for such solutions, particularly given concerns about long-term affordability and frailty associated with chronic GLP-1 use. The existing GI clinic infrastructure is already equipped for the procedure, facilitating adoption.
Disciplined Capital Management Through Key Milestones
Fractyl Health ended Q2 2026 with $47.1 million in cash, providing a runway into early 2027, which extends beyond the anticipated Revita pivotal data readout and potential de novo submission. The company emphasized a deliberate choice to operate within its existing capital envelope, with no plans to raise capital before pivotal data is in hand, signaling management's alignment with shareholders. Cash used in operations was approximately $16 million in Q2, reflecting a post-randomization run rate.
Rejuva Gene Therapy Platform Advances to Clinical Stage
The Rejuva program, a smart GLP-1 gene therapy targeting long-term metabolic remission from a single dose, received clinical trial authorization in the Netherlands and Ethics Committee approval in Australia for its Phase 1-2 first-in-human study of Rejuva-001. This AAV-based gene therapy aims to enable nutrient-responsive GLP-1 expression within the pancreas, avoiding systemic side effects. Preliminary data from this study, focusing on safety and tolerability, is expected in the second half of 2026, with its development funded within the existing capital runway.